Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Cell Reports. Medicine
|
November 26, 2024
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
Jean-Philippe Guégan, Florent Peyraud, Bérengère Dadone-Montaudie, et al.
Future Oncology (London, England)
|
March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Journal of Clinical Medicine
|
March 25, 2022
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
European Urology
|
June 4, 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
Emeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
Mihaela Aldea, Laurent Lam, Emeline Orillard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Cell Reports. Medicine
|
November 26, 2024
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
Jean-Philippe Guégan, Florent Peyraud, Bérengère Dadone-Montaudie, et al.
Future Oncology (London, England)
|
March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Journal of Clinical Medicine
|
March 25, 2022
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
European Urology
|
June 4, 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
Emeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
Mihaela Aldea, Laurent Lam, Emeline Orillard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
Page
of 10